Are Wall Street Analysts Bullish on Zimmer Biomet Stock?
Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.
How this was made
%252FZimmer%252520Biomet%252520headquarters_By%252520jetcityimage.jpeg&w=3840&q=75)
The 30-second read
Why it matters
ZBH’s Q2 beat and full-year EPS guidance provide a concrete earnings anchor, while the analyst-rating distribution (mostly Hold) suggests the market may require additional evidence on international stabilization or margin recovery.
Market read
Traders get a post-earnings snapshot with specific EPS/revenue beats, guidance range, and current Street rating/target distribution that can influence near-term positioning.
What to watch
The consensus rating is still mostly Hold, so the market may already be pricing the beat; the key swing factor is whether international procurement and price erosion stabilize beyond the current quarter.
Background
The piece compares ZBH’s performance versus the S&P 500 and the iShares U.S. Medical Devices ETF, then ties results to domestic hip momentum and international procurement/pricing pressures.
Ticker impact
Zimmer Biomet reported Q2 adjusted EPS of $2.07 vs $2.01 and revenue of $2.2B vs $2.1B, plus full-year EPS guidance $8.47 to $8.59.
Near-term bias modestly higher as the guidance range and beat reinforce expectations, but upside may be capped by the prevailing Hold rating mix.
Fresh, numeric earnings and guidance are provided, and the piece also cites a specific analyst price target implying limited upside versus the broader consensus.
Market effects
Medical device demand and pricing dynamics are highlighted via hip share gains offset by China procurement and non-core softness.
China volume-based procurement is cited as a headwind, implying continued regional margin pressure risk.
International pricing and procurement trends are positioned as a key swing factor for global med-tech earnings durability.
Counterpoint
Despite the EPS beat, the article emphasizes international headwinds and margin pressure from sales-force and new manufacturing investments, which could limit follow-through.
Key entities
- companyZimmer Biomet Holdings, Inc.
Medical device manufacturer whose Q2 results and full-year EPS guidance are the core disclosure.
- analyst_firmTruist Financial Corporation
Maintained a Hold rating and set a $106 price target for ZBH.
